Format

Send to

Choose Destination
Appl Health Econ Health Policy. 2018 Aug;16(4):495-502. doi: 10.1007/s40258-018-0392-8.

Uptake of and Expenditure on Direct-Acting Antiviral Agents for Hepatitis C Treatment in Australia.

Author information

1
Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia. Barbara.degraaff@utas.edu.au.
2
School of Medicine, University of Tasmania, Hobart, Australia.
3
School of Population and Global Health, University of Melbourne, Parkville, Australia.
4
Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.

Abstract

BACKGROUND:

Direct-acting antiviral agents (DAAs) have revolutionised treatment for the hepatitis C virus (HCV). Currently, treatment costs between 20,000 and 80,000 Australian dollars ($A) per patient. The Australian Federal Government provided $A1 billion over 5 years to subsidise these drugs.

OBJECTIVE:

The aim of this paper was to evaluate the uptake and financial impact of DAA prescribing in Australia.

METHODS:

We undertook a retrospective analysis of Medicare prescription and expenditure data for March 2016 to August 2017. Prescription numbers and expenditure data were extracted from the Medicare Statistical Reports website. Numbers of prescriptions were converted to per capita rates. HCV prevalence measures were used to provide context to prescription rates. All costs were reported in $A, year 2017 values.

RESULTS:

Nationally, 211,184 DAA prescriptions were reimbursed. Whilst $A3.6 billion was expended through the Pharmaceutical Benefits Scheme, confidential pricing agreements precluded calculation of the precise cost. In 18 months, estimated expenditure greatly exceeded the $A1 billion in funding for 5 years. Nationally, the rate of prescriptions was 872/100,000 individuals. Prescription rates were highest in the Australian Capital Territory (1087/100,000) and lowest in Western Australia (625/100,000) despite HCV prevalence being comparable to the national rate in both regions.

CONCLUSIONS:

Uptake of DAAs has been enthusiastic in the first 18 months of this funding agreement. However, the lack of transparency due to the confidential special pricing agreements means actual government expenditure is unknown. Post-marketing review by the Pharmaceutical Benefits Advisory Committee may enable renegotiation of DAA prices with the sponsors.

PMID:
29675692
DOI:
10.1007/s40258-018-0392-8

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center